Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-10-31 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于召开2024年第三次临时股东大会通知公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about the convening of the 2024 third extraordinary general meeting of shareholders for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and attachments such as proxy forms and registration forms. There is no financial data or results reported, nor is it a transcript or presentation. It is clearly a formal announcement to shareholders about the upcoming shareholders meeting and how to participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2024-10-31 Chinese
上海泓博智源医药股份有限公司2024年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed summary draft of a 2024 restricted stock incentive plan for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes extensive information about the plan's purpose, legal basis, management, scope, stock source, quantity, allocation, effective period, grant date, vesting arrangements, price determination, and conditions for granting and vesting. The document references relevant laws and regulations, stock incentive mechanisms, and detailed tables of stock allocation and vesting schedules. It is not a financial report, earnings release, or regulatory announcement but a comprehensive plan document related to stock-based compensation for management and key employees. This type of document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans.
2024-10-31 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2024. The document explicitly states it is a quarterly report and is unaudited. The length of the document (13,322 characters) and the presence of comprehensive financial statements and analysis confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-27 Chinese
第三届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It reports on the approval of the company's 2024 third quarter report and other financial decisions. The document is short (1249 characters) and does not contain the actual financial statements or detailed financial data but rather confirms the supervisory board's review and approval of the third quarter report and other matters. It also references that the full 2024 third quarter report is disclosed elsewhere (on the cninfo website). This fits the pattern of a meeting resolution announcement or supervisory board meeting decision announcement rather than the actual interim/quarterly report itself. Given the options, this is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board resolutions and approvals, not the full report or detailed financial data. The document is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, only referencing the report. It is not an AGM Information or Board/Management Information filing since it concerns the Supervisory Board meeting resolutions, which is a regulatory announcement type. Therefore, the best fit is Regulatory Filings (RNS).
2024-10-27 Chinese
第三届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the third board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results. The key agenda items include approval of the 2024 third quarter report and decisions regarding the use of surplus raised funds. The document references the 2024 third quarter report but does not contain the report itself; instead, it directs readers to the full report on an external website. The document is primarily about board meeting resolutions and decisions, not the financial report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and management resolutions.
2024-10-27 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司部分募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the completion of certain fundraising investment projects by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. and the permanent supplementation of surplus raised funds into working capital. It references regulatory guidelines on fundraising management, details the fundraising amounts, usage, surplus, and the company's board and supervisory approvals. The document is not a full annual or interim financial report, nor is it an earnings release or a call transcript. It is a regulatory compliance and verification report related to the use of raised funds, including the approval process and the sponsor's opinion. The document length is 4131 characters, which is relatively short but contains substantive content about fundraising project completion and fund usage verification, not merely an announcement or a certification. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it updates on the use and management of capital raised through the IPO and the changes in the use of those funds.
2024-10-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.